| NCT06161974 | Study of Olutasidenib and Temozolomide in HGG | RECRUITING | PHASE2 | 2025-03 | 2035-06 | 2029-06 |
| NCT05308264 | Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) | RECRUITING | PHASE1, PHASE2 | 2022-09-12 | 2026-12 | 2026-08 |
| NCT04629703 | Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects | COMPLETED | PHASE3 | 2021-03-25 | 2022-09-05 | 2022-09-05 |
| NCT04138927 | A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia | ENROLLING_BY_INVITATION | PHASE3 | 2019-10-30 | 2024-04 | 2024-04 |
| NCT03764618 | A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA | COMPLETED | PHASE3 | 2019-04-24 | 2022-04-11 | 2022-04-11 |
| NCT02612558 | A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA) | COMPLETED | PHASE2 | 2016-07 | 2019-12 | 2019-12 |
| NCT02433236 | Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy | WITHDRAWN | PHASE2 | 2015-09 | | 2015-09 |
| NCT02076412 | A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) | COMPLETED | PHASE3 | 2015-01 | 2016-08 | 2016-08 |
| NCT02077192 | Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) | COMPLETED | PHASE3 | 2014-10 | 2020-06-02 | 2020-06-02 |
| NCT02112838 | Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy | COMPLETED | PHASE2 | 2014-10 | 2018-11-12 | 2018-03-23 |
| NCT02076399 | A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) | COMPLETED | PHASE3 | 2014-07-14 | 2016-04-21 | 2016-04-21 |
| NCT02040623 | Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2) | COMPLETED | PHASE2 | 2014-03 | 2016-07 | 2016-07 |
| NCT01900249 | To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca | COMPLETED | PHASE2 | 2013-07 | 2014-07 | 2014-07 |
| NCT01733992 | A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease | COMPLETED | PHASE1 | 2012-11 | 2013-02 | 2013-02 |
| NCT01597050 | Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions | COMPLETED | PHASE2 | 2012-08 | 2013-09 | 2013-09 |
| NCT01591044 | A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma | COMPLETED | PHASE2 | 2012-07 | 2013-07 | 2013-07 |
| NCT00798096 | Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma | COMPLETED | PHASE2 | 2009-03 | 2010-04 | 2010-04 |
| NCT00752999 | Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus | WITHDRAWN | PHASE2 | 2008-11 | 2010-03 | 2009-11 |
| NCT00665626 | Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3) | COMPLETED | PHASE2 | 2008-05 | 2009-06 | 2009-06 |
| NCT00665925 | Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis | COMPLETED | PHASE2 | 2008-05 | 2009-06 | 2009-06 |
| NCT00446095 | Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma | COMPLETED | PHASE1, PHASE2 | 2007-04 | 2010-10 | 2010-04 |
| NCT00706342 | Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP) | COMPLETED | PHASE2 | 2007-01 | 2010-04 | 2010-04 |
| NCT00326339 | Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1) | COMPLETED | PHASE2 | 2006-08 | 2007-12 | 2007-10 |
| NCT00115089 | 7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seasonal Allergic Rhinitis | COMPLETED | PHASE2 | 2005-07 | 2005-09 | |